Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elexacaftor/tezacaftor/ivacaftor in cystic fibrosis with F508del and minimal function mutation
NCT04969224Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Oct 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, open-label, single-arm trial of elexacaftor + tezacaftor + ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Primary endpoint: Percent Reduction From Baseline in Cough Frequency (Cough Events Per Day) to the Average of Week 8 Through Week 12. Started Oct 2021; status: completed.
02
Drugs
elexacaftor + tezacaftor + ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT04969224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04969224.